Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: Pooled analysis of three randomized studies

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 21, Issue 10, 2014, Pages 761-766

  Yanagimoto, Hiroaki ^a   Ishii, Hiroshi ^b   Nakai, Yousuke ^c   Ozaka, Masato ^b   Ikari, Takaaki ^b   Koike, Kazuhiko ^c   Ueno, Hideki ^d   Ioka, Tatsuya ^e   Satoi, Sohei ^a   Sho, Masayuki ^f   Okusaka, Takuji ^d   Tanaka, Masao ^g   Shimokawa, Toshio ^h   Kwon, A Hon ^a   Isayama, Hiroyuki ^c  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^f NARA MEDICAL UNIVERSITY   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

^h UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Gemcitabine with S 1; Locally advanced pancreatic cancer; Pooled analysis

Indexed keywords

GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CONTROLLED STUDY; DRUG COMBINATION; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PANCREATIC NEOPLASMS; RISK; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 84927633457     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.130     Document Type: Conference Paper

References (27)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403-2413.
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-1966.
4. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369: 1691-1703.
5. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817-1825.
6. Saif MW, Chabot J,. Chemotherapy: metastatic pancreatic cancer-is FOLFIRINOX the new standard? Nat Rev Clin Oncol. 2011; 8: 452-453.
7. Nakamura K, Yamaguchi T, Ishihara T, Kobayashi A, Tadenuma H, Sudo K, et al. Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 2005; 92: 2134-2139.
8. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H,. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 2006; 94: 1575-1579.
9. Oh DY, Cha Y, Choi IS, Yoon SY, Choi IK, Kim JH, et al. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Cancer Chemother Pharmacol. 2010; 65: 527-536.
10. Kim MK, Lee KH, Jang BI, Kim TN, Eun JR, Bae SH, et al. S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer. Jpn J Clin Oncol. 2009; 39: 49-53.
11. Lee GW, Kim HJ, Ju JH, Kim SH, Kim HG, Kim TH, et al. Phase II trial of S-1 in combination with gemcitabine for chemo-naive patients with locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009; 64: 707-713.
12. Ueno H, Okusaka T, Ikeda M, Ishiguro Y, Morizane C, Matsubara J, et al. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology. 2005; 69: 421-427.
13. Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013; 31: 1640-1648.
14. Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Toda N, et al. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Br J Cancer. 2012; 106: 1934-1939.
15. Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, Mouri H, et al. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Cancer Chemother Pharmacol. 2012; 69: 1197-1204.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
17. Whitehead A, Whitehead J,. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med. 1991; 10: 1665-1677.
18. Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, et al. A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2008; 61: 615-621.
19. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009; 27: 5660-5669.
20. Satoi S, Yamaue H, Kato K, Takahashi S, Hirono S, Takeda S, et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2013; 20: 590-600.
21. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA,. Combined 5-fluorourail and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969; 2: 865-867.
22. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation 5-fluorouracil. Cancer. 1981; 48: 1705-1710.
23. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988; 80: 751-755.
24. Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D,. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009; 27: 2269-2277.
25. Tada M, Arizumi T, Nakai Y, Sasaki T, Kogure H, Togawa O, et al. Efficacy of gemcitabine for locally advanced pancreatic cancer: comparison with 5-fluorouracil-based chemoradiotherapy. Chemotherapy. 2008; 54: 302-308.
26. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008; 19: 1592-1599.
27. Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group Trial. J Clin Oncol. 2011; 29: 4105-4112.